Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection experience and quality of life after switching from goserelin acetate implant to injectable goserelin microspheres in premenopausal breast cancer
ChiCTR2500103194Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- May 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of goserelin in breast cancer, sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Pain score. Planned start May 2025; status: not yet recruiting.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500103194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103194.